Congratulations to #TBCPartner Verona Pharma! Yesterday’s FDA approval of their drug for the maintenance treatment of #COPD marks a significant advance for patients as the first inhaled product with a novel mechanism of action in more than two decades – a game-changing advancement in the standard of care. https://lnkd.in/e9d4s8GH
Ten Bridge Communications
Public Relations and Communications Services
Boston, MA 4,385 followers
We guide biotech through the big moments.
About us
We work with biotech innovators at all stages of growth and development, whether they are launching anew or advancing a potentially transformative medicine through regulatory approval and beyond. Our work is guided by a deep curiosity about our partners’ science and patient focus and a commitment to elevating them and their message to the world. Relationships – both with our partners and across biotech – are critical ingredients of our success.
- Website
-
https://www.tenbridgecommunications.com/
External link for Ten Bridge Communications
- Industry
- Public Relations and Communications Services
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Company launches, corporate branding & creative services, strategic communications planning & execution, patient engagement & advocacy support, product approval & launch communications, and milestone-related media and communications
Locations
-
Primary
One Beacon Street
8th Floor
Boston, MA 02108, US
Employees at Ten Bridge Communications
-
Chris Railey
Vice President at Ten Bridge Communications
-
Florence Chan, SHRM-SCP
Head of Human Resources at Ten Bridge Communications
-
Leslie (Priest) Humbel
Strategic healthcare communicator, marketer and client manager
-
Josh Madej, MS, MBA
Wellness Entrepreneur I Care-tech Founder I Biotech Marketer I Former Patient & Caregiver
Updates
-
#TBCPartner X4 Pharmaceuticals' momentum continues with the announcement of interim data from its ongoing Phase 2 trial of mavorixafor, the company’s oral CXCR4 antagonist, in chronic neutropenia. Chronic neutropenia is a rare condition in which patients’ low levels of neutrophils in the blood lead to higher risk of developing infections and reduced quality of life. It’s exciting to see progress toward a new treatment option for these patients.
Today, we announced positive interim data from our ongoing Phase 2 trial evaluating the safety and efficacy of our product candidate in people with #ChronicNeutropenia (CN). We also announced that we’ve started screening patients for enrollment into our pivotal Phase 3 trial, the 4WARD study, to evaluate our product candidate in people with congenital, acquired primary autoimmune, or idiopathic CN. We’re hosting a webinar today at 8:00 am ET and will detail the interim results, feature clinical experts in the treatment of CN, and discuss the 4WARD study. Learn more here: https://lnkd.in/eaDtEtT6 #Progress4Patients
-
-
#TBCPartner Intellia Therapeutics, Inc. continues to push the boundaries of #CRISPR genome editing. While the goal of their therapies in development is to be one-and-done, new data suggest that the editing technology can potentially be redosed, which may have advantages in certain contexts.
Can #CRISPR be given twice? Small study from Intellia Therapeutics, Inc. suggests it can. But why would you want a CRISPR therapy twice? Isn't this supposed to be one-and-done? Yes, but there are some cases where 2 or 3 doses could help. My story for Endpoints News explains: https://lnkd.in/exhh8u2R #biotech #geneediting #genetherapy #drugdevelopment #geneticmedicine #lipidnanoparticle
Can CRISPR be given twice? Small study from Intellia suggests it can
https://endpts.com
-
It was a privilege to work alongside #TBCPartner HC Bioscience, Inc. on their new brand and website. A leader in #tRNA-based therapies, they are pioneering a new approach in protein editing, with programs in #hemophilia and #DMD. Their new site dives into the science behind tRNA, their platform for treating genetic diseases, and their lead programs. Give the new site a look.
We’re excited to unveil our new website! It serves as a hub to showcase HC Bioscience’s pioneering work in engineering tRNAs to overwrite faulty genes. Our protein editing approach corrects disease-causing mutations without altering DNA or mRNA, with one therapeutic tRNA having the potential to address a broad spectrum of genetically driven diseases. Explore our site to learn more about our #tRNA technology, our amazing team, and our collective drive to transform patients’ lives. [https://bit.ly/4evG8iD]
-
We want to extend our congratulations to #TBCPartner Sarepta Therapeutics and the entire Duchenne community on last night’s monumental FDA decision. With the expanded label, Sarepta’s gene therapy is now approved for the majority of patients with Duchenne muscular dystrophy.
BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment. Intended for U.S. audiences
-
-
We are thrilled to welcome Jesena Kalabokis to team TBC via Project Onramp! Jesena joins us from the University of Massachusetts Amherst where she is currently majoring in journalism with a minor in environmental science. In her free time at UMass, she manages a radio station where she plays a different genre of music every week. Welcome, Jesena – we’re looking forward to an exciting and engaging summer!
-
-
Last week #TBCPartner X4 Pharmaceuticals' Founder, CEO & President Paula Ragan, Ph.D., was joined by BiotechTV's Brad Loncar in X4’s vibrant Boston HQ for a discussion on the company's newly FDA approved treatment for an ultra-rare disease and what's on the horizon.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: X4 Pharmaceuticals' CEO Paula Ragan, Ph.D. on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications. She describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month. Full video: https://lnkd.in/gzMpmhiB BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Congrats to #TBCPartner Rapport Therapeutics on their $154M IPO. We can’t wait to see how their RAP-based platform leads to new possibilities in addressing CNS disease.
Huge thanks to Nasdaq for helping us to celebrate our very first trade as $RAPP. Today was a major milestone for the Rapport team as we continue to advance our mission to deliver transformational medicines for patients with CNS disorders. We can’t wait for the next leg of our journey! #NasdaqListed $RAPP #IPO #CentralNervousSystemDisorders #NeurologicalHealthcare #Neuromedicine #Neuroscience #Biotech #RapportIPO
-
-
Another important milestone for #TBCPartner Intellia Therapeutics, Inc., who announced positive long-term data from its in vivo Phase 1 study of NTLA-2002 for hereditary angioedema (HAE). NTLA-2002 continues to show durable reduction of monthly attack rates with just a single dose, and potential to be a functional cure for people living with this rare disease. Fantastic progress for in vivo gene editing, the field of genomic medicine and #CRISPR technology!
Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at the European Academy of Allergy and Clinical Immunology - EAACI 2024 Congress. Full details here: https://lnkd.in/evkqTURF #HAE #CRISPR #geneediting
-
Last week was an exciting one for TBC. Not only did we have some warm, sunny weather, we had nearly all our team members in Boston for our quarterly week of in-person team building and collaboration. We put our engineering minds to the test, seeing who could build the tallest structure using tape, spaghetti and a marshmallow top. Our winners came in at a towering 21 inches. It also proved that the bridge building we do here at TBC will remain strictly metaphorical. We also kicked off the summer early with an outing at Cisco Brewers in the Seaport, where we enjoyed some local brews and lawn games. Thank you to our amazing team members both local and remote for making the trip! Alexis Stefano Rachel S. Leslie (Priest) Humbel Christine Mackenzie
-